Bisphosphonate therapy for painless fracture: change of HSAN 1 clinical course with biphosphonate and Vitamin D therapy

J Musculoskelet Neuronal Interact. 2012 Sep;12(3):165-73.

Abstract

Hereditary Sensory and Autonomic Neuropathies comprise a set of 5 rare neurologic conditions, little known to radiologists as the neurologic and skin abnormalities precede the radiographic changes by months or even years. We report a Caucasian patient with a clinical history of HSAN, most consistent with subtype 1, whose progressive, destructive bone changes of the foot were not only controlled but to a degree reversed by the administration of bisphosphonates (Alendronate ) and vitamin D (Colecalciferol). The authors believe that combined bisphosphonate and vitamin D therapy is the treatment of choice for progressive bony changes in HSAN1. This therapy may be beneficial in other neuropathic osteoarthropathies and possibly osteolytic bone disorders.

Publication types

  • Case Reports

MeSH terms

  • Alendronate / therapeutic use*
  • Cholecalciferol / therapeutic use*
  • Diphosphonates / therapeutic use*
  • Female
  • Fractures, Bone / drug therapy*
  • Fractures, Bone / etiology
  • Hereditary Sensory and Autonomic Neuropathies / complications
  • Hereditary Sensory and Autonomic Neuropathies / drug therapy*
  • Hereditary Sensory and Autonomic Neuropathies / physiopathology
  • Humans
  • Vitamin D / therapeutic use*

Substances

  • Diphosphonates
  • Vitamin D
  • Cholecalciferol
  • Alendronate